PGAM5 is a key driver of mitochondrial dysfunction in experimental lung fibrosis.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 08 01 2019
accepted: 06 05 2019
pubmed: 7 6 2019
medline: 26 11 2019
entrez: 7 6 2019
Statut: ppublish

Résumé

Mitochondrial homeostasis has recently emerged as a focal point in the pathophysiology of idiopathic pulmonary fibrosis (IPF), but conflicting data have been reported regarding its regulation. We speculated that phosphoglycerate mutase family member 5 (PGAM5), a mitochondrial protein at the intersection of multiple cell death and mitochondrial turnover pathways, might be involved in the pathogenesis of IPF. PGAM5-deficient mice and human pulmonary epithelial cells were analyzed comparatively with PGAM5-proficient controls in a bleomycin-based model of pulmonary fibrogenesis. Mitochondria were visualized by confocal and transmission electron microscopy. Mitochondrial homeostasis was assessed using JC1 (ΔΨ) and flow cytometry. PGAM5 plays an important role in pulmonary fibrogenesis. Pgam5-/- mice displayed significantly attenuated lung fibrosis compared to controls. Complementary, in vitro studies demonstrated that PGAM5 impaired mitochondrial integrity on a functional and structural level independently of mtROS-production. On a molecular level, reduced mitophagy caused by PGAM5 deficiency improved mitochondrial homeostasis. Our study identifies PGAM5 as an important regulator of mitochondrial homeostasis in pulmonary fibrosis. Our data further indicate PGAM5-mediated mitophagy itself as a pivotal gateway event in the mediation of self-sustaining mitochondrial damage and membrane depolarization. Our work hereby highlights the importance of mitochondrial dynamics and identifies a potential therapeutic target that warrants further studies. Toxic agents lead to mitochondrial damage resulting in depolarization of the mitochondrial membrane potential (ΔΨ) which is a gateway event for the initiation of PGAM5-mediated mitophagy. PGAM5-mediated mitophagy in turn leads to a self-perpetuating escalation of ΔΨ depolarization. Loss of the mitophagy-based damage-enhancing loop under PGAM5-deficient conditions breaks this vicious cycle, leading to improved mitochondrial homeostasis.

Identifiants

pubmed: 31168659
doi: 10.1007/s00018-019-03133-1
pii: 10.1007/s00018-019-03133-1
doi:

Substances chimiques

MAP1LC3A protein, human 0
MAP1LC3B protein, human 0
Microtubule-Associated Proteins 0
Reactive Oxygen Species 0
Bleomycin 11056-06-7
Protein Kinases EC 2.7.-
PTEN-induced putative kinase EC 2.7.11.1
Phosphoprotein Phosphatases EC 3.1.3.16

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4783-4794

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : BE3686/2
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : FOR2438
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : SFB1181
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : SFB796
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : SPP1656
Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : KFO257
Organisme : Interdisciplinary Center for Clinical Research (IZKF) Erlangen
ID : Forschungsrotation
Organisme : Interdisciplinary Center for Clinical Research (IZKF) Erlangen
ID : Project A75

Références

Nat Cell Biol. 2018 Mar;20(3):272-284
pubmed: 29459781
J Clin Pathol. 1988 Apr;41(4):467-70
pubmed: 3366935
Am J Respir Cell Mol Biol. 2011 May;44(5):725-38
pubmed: 21531958
Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10190-5
pubmed: 21646527
Am J Respir Crit Care Med. 2001 Oct 1;164(7):1171-81
pubmed: 11673205
J Clin Invest. 2015 Feb;125(2):521-38
pubmed: 25562319
Autophagy. 2011 Oct;7(10):1251-3
pubmed: 21743300
J Immunol. 2016 Jan 1;196(1):407-15
pubmed: 26582950
Toxicol Lett. 2018 Mar 1;284:120-128
pubmed: 29241732
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Free Radic Biol Med. 2016 Dec;101:482-490
pubmed: 27840320
Redox Biol. 2015;4:215-25
pubmed: 25617802
Gut. 2017 Apr;66(4):716-723
pubmed: 27566130
PLoS One. 2015 Mar 18;10(3):e0121246
pubmed: 25785991
J Clin Invest. 2014 Sep;124(9):3987-4003
pubmed: 25083992
Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L433-52
pubmed: 27402690
Nat Protoc. 2007;2(2):287-95
pubmed: 17406588
N Engl J Med. 2013 Feb 14;368(7):651-62
pubmed: 23406030
PLoS One. 2016 Jan 25;11(1):e0147792
pubmed: 26807733
J Clin Invest. 2016 Mar 1;126(3):809-20
pubmed: 26928034
Nat Immunol. 2018 Feb;19(2):130-140
pubmed: 29255269
Nat Commun. 2014 Sep 15;5:4930
pubmed: 25222142
Immunity. 2016 Mar 15;44(3):582-596
pubmed: 26921108

Auteurs

Ingo Ganzleben (I)

Department of Medicine 1, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Gui-Wei He (GW)

Department of Medicine 1, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Claudia Günther (C)

Department of Medicine 1, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Elena-Sophie Prigge (ES)

Department of Applied Tumor Biology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Clinical Cooperation Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Karsten Richter (K)

Central Unit Electron Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Ralf J Rieker (RJ)

Department of Pathology, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Dimitrios Mougiakakos (D)

Department of Medicine 5, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Markus F Neurath (MF)

Department of Medicine 1, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Christoph Becker (C)

Department of Medicine 1, University Hospital, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. christoph.becker@uk-erlangen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH